Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier

Launched by CERBAXPERT · Apr 12, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how certain antibodies from a mother can be passed to her baby through the placenta during pregnancy. These antibodies, called anti-interferon type 1 alpha autoantibodies, are often found in women with specific health conditions like lupus, severe COVID-19, or type 1 diabetes. The main goal is to see how often these antibodies are transferred to newborns, especially in mothers who have these antibodies during their pregnancy.

To participate in this study, women need to be over 18 years old and pregnant with less than 30 weeks until their due date. They must also have a health condition commonly associated with these antibodies and agree to have a test done to check for them. Participants will give birth at the study center, and they should be part of the Social Security system. However, women who have had a recent blood transfusion, organ transplant, or certain heavy treatments for cancer are not eligible. This study is still in the planning stages and hasn't started recruiting participants yet. If you think you might be eligible and are interested in learning more, please talk to your healthcare provider.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Pregnant woman over 18 years old
• • Woman whose gestational age is less than 30 weeks.
• • Having agreed to carry out an assay of anti-IFN alpha IgG auto-Ac before 30 weeks
• • Give birth in the inclusion center
• • Suffering from a pathology frequently associated with the presence of these anti-autoantibodies IFN alpha (lupus, severe COVID-19, myasthenia gravis, incontinentia pigmenti, hypoparathyroidism, adrenal insufficiency, diffuse candidiasis, Biermer's disease, dysthyroidism, type 1 diabetes, celiac disease, auto-thyroid disease immune system such as Graves' disease, Hashimoto's thyroiditis) or knowing its positive anti-IFN alpha autoantibody status
• • Affiliated with the Social Security system
• Exclusion Criteria:
• • Patient who underwent a blood transfusion less than 2 months ago
• • Patient who received an organ transplant
• • Patient undergoing immunotherapy, stem cell therapy and/or other malignancy maternal, under heavy treatment (chemotherapy) less than 6 months before inclusion